Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
Journal
The Lancet. Haematology
Journal Volume
2
Journal Issue
10
Pages
e417
Date Issued
2015-10
Author(s)
Platzbecker, Uwe
Wong, Raymond S M
Verma, Amit
Abboud, Camille
Araujo, Sergio
Chiou, Tzeon-Jye
Feigert, John
Yeh, Su-Peng
Götze, Katharina
Gorin, Norbert-Claude
Greenberg, Peter
Kambhampati, Suman
Kim, Yoo-Jin
Lee, Je-Hwan
Lyons, Roger
Ruggeri, Marco
Santini, Valeria
Cheng, Gregory
Jang, Jun Ho
Johnson, Brendan
Bennett, John
Mannino, Frank
Kamel, Yasser Mostafa
Stone, Nicole
Dougherty, Souria
Chan, Geoffrey
Giagounidis, Aristoteles
Abstract
Patients with myelodysplastic syndrome or acute myeloid leukaemia who are thrombocytopenic and unable to receive disease-modifying therapy have few treatment options. Platelet transfusions provide transient benefit and are limited by alloimmunisation. Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet counts and has preclinical antileukaemic activity. We aimed to assess the safety and tolerability of eltrombopag for the treatment of thrombocytopenia in adult patients with advanced myelodysplastic syndrome, secondary acute myeloid leukaemia after myelodysplastic syndrome, or de-novo acute myeloid leukaemia.
SDGs
Type
journal article